2019
DOI: 10.1136/gutjnl-2018-317807
|View full text |Cite
|
Sign up to set email alerts
|

Diagnosis and management of acute lower gastrointestinal bleeding: guidelines from the British Society of Gastroenterology

Abstract: This is the first UK national guideline to concentrate on acute lower gastrointestinal bleeding (LGIB) and has been commissioned by the Clinical Services and Standards Committee of the British Society of Gastroenterology (BSG). The Guidelines Development Group consisted of representatives from the BSG Endoscopy Committee, the Association of Coloproctology of Great Britain and Ireland, the British Society of Interventional Radiology, the Royal College of Radiologists, NHS Blood and Transplant and a patient repr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

10
247
2
28

Year Published

2019
2019
2023
2023

Publication Types

Select...
6
2

Relationship

2
6

Authors

Journals

citations
Cited by 244 publications
(287 citation statements)
references
References 121 publications
10
247
2
28
Order By: Relevance
“…In patients with UGIB, a value over 1 has been suggested as a marker of active bleeding at the time of admission. It has also recently been proposed as part of a stratification scheme for patients with lower GI bleeding . The authors of the current paper found that the SI performed worse than existing pre‐endoscopy scores including the admission Rockall, AIMS65, and Glasgow‐Blatchford (GBS), at predicting major clinical endpoints after UGIB.…”
contrasting
confidence: 99%
“…In patients with UGIB, a value over 1 has been suggested as a marker of active bleeding at the time of admission. It has also recently been proposed as part of a stratification scheme for patients with lower GI bleeding . The authors of the current paper found that the SI performed worse than existing pre‐endoscopy scores including the admission Rockall, AIMS65, and Glasgow‐Blatchford (GBS), at predicting major clinical endpoints after UGIB.…”
contrasting
confidence: 99%
“…50,67 Séu einstaklingar án sögu um hjarta-eða aeðasjúkdóma á hjartamagnýli til forvarnar, maela erlendar leiðbeiningar með því að meðferð sé haett og ekki endurvakin nema skýr ástaeða þyki til. 49,50,57,67 Fyrir sjúklinga á tvöfaldri blóðflöguhamlandi meðferð er maelt með því að halda áfram meðferð ef þeir hafa blaeðingu frá efri hluta meltingarvegar nema ef speglun sýnir fram á blaeðandi sár eða sár með sýnilegri aeð, en þá er maelt með að halda áfram með hjartamagnýl en stöðva hitt blóðflöguhamlandi lyfið, fá í kjölfarið álit hjartalaeknis og endurvekja fulla blóðflöguhamlandi meðferð sem fyrst. 57 Hjá sjúklingum með blaeðingu frá neðri hluta meltingarvegar er maelt með því að halda áfram með tvöfalda blóðflöguhamlandi meðferð ef saga er um nýlegt kransaeðaheilkenni eða stoðnet.…”
Section: Framhald Og Horfurunclassified
“…57 Hjá sjúklingum með blaeðingu frá neðri hluta meltingarvegar er maelt með því að halda áfram með tvöfalda blóðflöguhamlandi meðferð ef saga er um nýlegt kransaeðaheilkenni eða stoðnet. 50,67 Ef ákveðið er að stöðva annað lyfið skal halda hjartamagnýl áfram en endurvekja fulla meðferð innan 5-7 daga. 50,67 Vísindagögnin á bak við þessar leiðbeiningar eru mjög takmörkuð og byggja aðallega á því að sýnt hefur verið fram á að dánartíðni einstaklinga sem haetta á blóðflöguhamlandi meðferð og eru með nýlegt stoðnet í kransaeð eða kransaeðaheilkenni er talsvert aukin.…”
Section: Framhald Og Horfurunclassified
See 1 more Smart Citation
“…[5][6][7] Other investigations include computed tomographic angiography, red blood cell scintigraphy, and digital subtraction angiography. 11 Once diagnostic testing has been undertaken, specific therapy can be performed. For those undergoing colonoscopy and specific lesions with bleeding stigmata are identified, definite endoscopic therapies can be performed.…”
mentioning
confidence: 99%